JD Esq - Opko Health Chief Laboratories
| OPK Stock | USD 1.58 0.02 1.28% |
Executive
JD Esq is Chief Laboratories of Opko Health
| Age | 64 |
| Address | 4400 Biscayne Boulevard, Miami, FL, United States, 33137 |
| Phone | 305 575 4100 |
| Web | https://www.opko.com |
Opko Health Management Efficiency
The company has Return on Asset of (0.0897) % which means that on every $100 spent on assets, it lost $0.0897. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.0939) %, meaning that it generated no profit with money invested by stockholders. Opko Health's management efficiency ratios could be used to measure how well Opko Health manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -0.41. The value of Return On Capital Employed is expected to slide to -0.09. At this time, Opko Health's Liabilities And Stockholders Equity is quite stable compared to the past year. Change To Liabilities is expected to grow at the current pace this year, although the value of Total Current Liabilities will most likely fall to about 103.9 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| MD MBA | Natera Inc | N/A | |
| Jennifer Low | 23Andme Holding Co | 55 | |
| Bas Verhoef | Illumina | N/A | |
| Kashif Rathore | Caredx Inc | N/A | |
| Sheetal Parmar | Natera Inc | N/A | |
| James Polewaczyk | IDEXX Laboratories | 60 | |
| Jakob Wedel | Illumina | N/A | |
| Kieran OKane | Biodesix | 47 | |
| Jacquie JD | 23Andme Holding Co | N/A | |
| Kathryne Reeves | Illumina | 55 | |
| Ken Grady | IDEXX Laboratories | N/A | |
| Reza MBA | 23Andme Holding Co | N/A | |
| Ellen Tsui | Fulgent Genetics | N/A | |
| Mark DeBlock | Biodesix | N/A | |
| Katie Watson | 23Andme Holding Co | 46 | |
| Scott Davies | Illumina | N/A | |
| William Richards | 23Andme Holding Co | 63 | |
| James MD | Biodesix | N/A | |
| Natalie Prescott | Fulgent Genetics | N/A | |
| John JD | Guardant Health | 51 | |
| Tobin Juvenal | Castle Biosciences | 64 | |
Management Performance
| Return On Equity | -0.0939 | ||||
| Return On Asset | -0.0897 |
Opko Health Leadership Team
Elected by the shareholders, the Opko Health's board of directors comprises two types of representatives: Opko Health inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opko. The board's role is to monitor Opko Health's management team and ensure that shareholders' interests are well served. Opko Health's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opko Health's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arie Gutman, Pres API | ||
| Dr MBA, Vice Officer | ||
| FACP FASN, Senior Renal | ||
| Adam Logal, CFO, Chief Accounting Officer, Sr. VP and Treasurer | ||
| David Okrongly, President Diagnostics | ||
| Antonio Cruz, President Therapeutics | ||
| Elias MD, President Chairman | ||
| JD Esq, Chief Laboratories | ||
| Charles Bishop, Chief Renal | ||
| Hans Berner, President Iberoamerica | ||
| James DeMarco, VP Sales | ||
| Giovanni MD, Chief Officer | ||
| Phillip Frost, Chairman of the Board, CEO | ||
| Akhtar Ashfaq, Senior Vice President - Clinical Research and Development of OPKO Health's Renal Division | ||
| MBA MBA, Vice Officer | ||
| Jon MD, Advisor |
Opko Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opko Health a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0939 | ||||
| Return On Asset | -0.0897 | ||||
| Profit Margin | (0.19) % | ||||
| Operating Margin | (0.62) % | ||||
| Current Valuation | 1.17 B | ||||
| Shares Outstanding | 672.8 M | ||||
| Shares Owned By Insiders | 54.45 % | ||||
| Shares Owned By Institutions | 28.02 % | ||||
| Number Of Shares Shorted | 95.86 M | ||||
| Price To Earning | 7.46 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Opko Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Opko Stock please use our How to buy in Opko Stock guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Opko Health. If investors know Opko will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Opko Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.191 | Earnings Share (0.19) | Revenue Per Share 0.998 | Quarterly Revenue Growth (0.03) | Return On Assets (0.09) |
The market value of Opko Health is measured differently than its book value, which is the value of Opko that is recorded on the company's balance sheet. Investors also form their own opinion of Opko Health's value that differs from its market value or its book value, called intrinsic value, which is Opko Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Opko Health's market value can be influenced by many factors that don't directly affect Opko Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Opko Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Opko Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Opko Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.